methyl-3 bicyclo<5.3.0>undecane | 85960-47-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: methyl-3 bicyclo<5.3.0>undecane
• 英文别名: methyl-3 bicyclo[5.3.0]undecane；2-Methyl-1,3,3a,4,5,6,7,8,9,9a-decahydrocycloocta[c]pyrrole
• CAS: 85960-47-0
• 化学式: C₁₁H₂₁N
• 分子量: 167.294
• InChiKey: HTASBDJFEQCVNV-UHFFFAOYSA-N

物化性质

• 沸点：
  222.8±8.0 °C(Predicted)
• 密度：
  0.893±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  顺-环辛烯 、 十二/十四烷基二甲基氧化胺 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 以90%的产率得到methyl-3 bicyclo<5.3.0>undecane
  参考文献：
  名称：

  三甲胺N-氧化物作为甲亚胺盐化物的前体

  摘要：

  通过用二异丙基氨基锂处理三甲胺N-氧化物而生成的第一个不具有稳定基团的偶氮甲碱叶立德与各种简单的烯烃进行现成的[3 + 2]环加成反应，从而得到高产率的相应吡咯烷。

  DOI：

  10.1039/c39830000031

文献信息

• Medical device with coating that promotes endothelial cell adherence and differentiation
  申请人：Kutryk Bradley Michael John

  公开号：US20070213801A1

  公开（公告）日：2007-09-13

  Compositions and methods are provided for producing a medical device such as a stent, a stent graft, a synthetic vascular graft, heart valves, coated with a biocompatible matrix which incorporates antibodies, antibody fragments, or small molecules, which recognize, bind to and/or interact with a progenitor cell surface antigen to immobilize the cells at the surface of the device. The coating on the device can also contain a compound or growth factor for promoting the progenitor endothelial cell to accelerate adherence, growth and differentiation of the bound cells into mature and functional endothelial cells on the surface of the device to prevent intimal hyperplasia. Methods for preparing such medical devices, compositions, and methods for treating a mammal with vascular disease such as restenosis, artherosclerosis or other types of vessel obstructions are disclosed.

  本发明提供了一种制备医疗器械的组合物和方法，例如支架、支架移植物、合成血管移植物、心脏瓣膜等，这些器械涂覆有生物相容性基质，其中包含抗体、抗体片段或小分子，它们识别、结合和/或与祖细胞表面抗原相互作用，以使细胞固定在器械表面。器械表面的涂层还可以含有化合物或生长因子，以促进祖细胞内皮细胞加速附着、生长和分化成为成熟和功能性内皮细胞，从而防止内膜增生。本发明还公开了制备这种医疗器械的方法、组合物和治疗哺乳动物血管疾病（如再狭窄、动脉粥样硬化或其他类型的血管阻塞）的方法。
• MEDICAL DEVICE WITH COATING FOR CAPTURING GENETICALLY-ALTERED CELLS AND METHODS FOR USING SAME
  申请人：Kutryk John Bradley Michael

  公开号：US20070191932A1

  公开（公告）日：2007-08-16

  Therapeutic and drug delivery systems are provided in the form of medical devices with coatings for capturing and immobilizing target cells such as circulating progenitor or genetically-altered mammalian cells in vivo. The genetically-altered cells are transfected with genetic material for expressing a marker gene and at least one therapeutic gene in a constitutively or controlled manner. The marker gene is a cell membrane antigen not found in circulating cells in the blood stream and therapeutic gene encodes a peptide for the treatment of disease, such as, vascular disease and cancer. The coating on the medical device may be a biocompatible matrix comprising at least one type of ligand, such as antibodies, antibody fragments, other peptides and small molecules, which recognize and bind the target cells. The therapeutic and/or drug delivery systems may be provided with a signal source such as activator molecules for stimulating the modified cells to express and secrete the desired marker and therapeutic gene products.

  提供治疗和药物传递系统，以医疗设备的形式，具有用于捕获和固定靶细胞的涂层，例如在体内循环的祖细胞或基因改造的哺乳动物细胞。基因改造的细胞被转染了用于表达标记基因和至少一种治疗基因的遗传材料，以常态或可控的方式。标记基因是血液循环中未发现的细胞膜抗原，治疗基因编码用于治疗疾病的肽，例如血管疾病和癌症。医疗设备上的涂层可以是生物相容性矩阵，包括至少一种配体，例如抗体、抗体片段、其他肽和小分子，这些配体可以识别和结合靶细胞。治疗和/或药物传递系统可以配备信号源，例如激活分子，用于刺激改造的细胞表达和分泌所需的标记和治疗基因产物。
• MEDICAL DEVICE WITH COATING THAT PROMOTES ENDOTHELIAL CELL ADHERENCE AND DIFFERENTIATION
  申请人：Kutryk Michael J. B.

  公开号：US20130172988A1

  公开（公告）日：2013-07-04

  Compositions and methods are provided for producing a medical device such as a stent, a stent graft, a synthetic vascular graft, heart valves, coated with a biocompatible matrix which incorporates antibodies, antibody fragments, or small molecules, which recognize, bind to and/or interact with a progenitor cell surface antigen to immobilize the cells at the surface of the device. The coating on the device can also contain a compound or growth factor for promoting the progenitor endothelial cell to accelerate adherence, growth and differentiation of the bound cells into mature and functional endothelial cells on the surface of the device to prevent intimal hyperplasia. Methods for preparing such medical devices, compositions, and methods for treating a mammal with vascular disease such as restenosis, artherosclerosis or other types of vessel obstructions are disclosed.

  提供了制备医疗器械（如支架、支架嵌套管、合成血管移植物、心脏瓣膜等）的组合物和方法，这些医疗器械涂有生物相容性基质，该基质包含抗体、抗体片段或小分子，这些抗体、抗体片段或小分子能够识别、结合和/或与祖细胞表面抗原相互作用，以使细胞固定在器械表面。器械表面的涂层还可以含有化合物或生长因子，以促进祖细胞内皮细胞加速附着、生长和分化，使绑定的细胞成熟并在器械表面形成功能性内皮细胞，从而预防内膜增生。公开了制备此类医疗器械、组合物和治疗哺乳动物血管疾病（如再狭窄、动脉粥样硬化或其他类型的血管阻塞）的方法。
• Positive allosteric modulators of muscarinic M2 receptor
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US10435403B2

  公开（公告）日：2019-10-08

  The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.

  本申请涉及毒蕈碱 M2 受体的正性异位调节剂，特别是新型 7-取代 1-芳基萘啶-3-羧酰胺，涉及其制备工艺，涉及其单独或组合用于治疗和/或预防疾病，以及涉及其用于生产治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病和/或肾脏疾病。
• Beugelmans, Rene; Benadjila-Iguertsira, Leila; Chastanet, Jacqueline, Canadian Journal of Chemistry, 1985, vol. 63, p. 725 - 734
  作者：Beugelmans, Rene、Benadjila-Iguertsira, Leila、Chastanet, Jacqueline、Negron, Guillermo、Roussi, Georges

  DOI：——

  日期：——